The Persistent Challenge of Smoking in America
Smoking remains one of the leading preventable causes of death in the United States, claiming over 480,000 lives annually according to the Centers for Disease Control and Prevention (CDC). Despite decades of public health campaigns, nicotine replacement therapies, and medications like varenicline (Chantix), long-term quit rates hover around 20-30% for most treatments. In 2022, about 11.6% of U.S. adults—roughly 28.8 million people—were current cigarette smokers, with higher rates among certain demographics like those with lower education or income levels. This epidemic underscores the urgent need for innovative, more effective interventions, particularly as tobacco use contributes to diseases like lung cancer, heart disease, and chronic obstructive pulmonary disease (COPD).
Traditional approaches target nicotine receptors directly, but relapse is common due to psychological dependence, cravings, and habitual behaviors. Enter psilocybin, the psychoactive compound found in certain mushrooms, which researchers at Johns Hopkins University School of Medicine are exploring as a paradigm-shifting adjunct therapy.
Johns Hopkins' Legacy in Psychedelic Research
Johns Hopkins University has been at the forefront of psychedelic research since the early 2000s, establishing the Center for Psychedelic and Consciousness Research in 2019. This center, housed within the Department of Psychiatry and Behavioral Sciences, has pioneered studies on psilocybin for conditions ranging from depression and anxiety to addiction. Lead researcher Matthew W. Johnson, PhD, has been instrumental, building on a 2014 open-label pilot study where 80% of 15 long-term smokers achieved abstinence at six months—a rate far surpassing standard treatments.
The center's work received a National Institutes of Health (NIH) grant specifically for psilocybin in tobacco addiction, highlighting institutional commitment to translating ancient substances into modern medicine. Collaborators like Peter S. Hendricks and Albert Garcia-Romeu from the same department co-authored the latest trial, demonstrating Johns Hopkins' multidisciplinary approach involving psychiatry, neuroscience, and behavioral therapy.
Design and Methods of the Groundbreaking Pilot Trial
Published on March 10, 2026, in JAMA Network Open, the pilot randomized clinical trial (RCT) enrolled 82 psychiatrically healthy adult smokers (mean age 47.6 years, 59.8% male) at Johns Hopkins Bayview Medical Center in Baltimore. Participants, who smoked an average of 15.7 cigarettes daily and had a median of six prior quit attempts, were randomized 1:1 to two arms:
- Psilocybin arm: Single high dose (30 mg/70 kg body weight) administered in a supportive setting with eye shades and music, paired with 13 weeks of manualized cognitive behavioral therapy (CBT) for smoking cessation.
- Control arm: Nicotine patch (8-10 weeks per FDA guidelines) plus identical CBT.
A target quit date was set in week 5, with daily post-quit support. Outcomes were biochemically verified using exhaled carbon monoxide and urinary cotinine, with primary endpoint prolonged abstinence at six months (no smoking after a two-week grace period). The unblinded design accounted for psilocybin's unmistakable effects, but optional crossover minimized dropout.
Impressive Results: Psilocybin's Superior Efficacy
The results were striking: 40.5% (17/42) in the psilocybin group achieved prolonged six-month abstinence versus 10.0% (4/40) in the nicotine patch group—an odds ratio of 6.12 (95% CI, 1.99-23.26; P = .003). For seven-day point prevalence abstinence, rates were 52.4% versus 25.0% (OR 3.30; P = .01). Psilocybin participants smoked fewer cigarettes post-quit (model-predicted 1.69 vs. 3.64 per day; IRR 0.04; P = .002).
These rates eclipse nicotine patch benchmarks (typically 10-20% at six months) and approach or exceed varenicline's 25-33% in head-to-head trials. Johnson noted the 'magnitude of the effect' surprised the team, building on prior open-label data.
Mechanisms: Beyond Nicotine Receptors
Unlike nicotine patches or varenicline, which mimic or block nicotine at acetylcholine receptors, psilocybin—a serotonin 2A (5-HT2A) receptor agonist—induces profound mystical experiences fostering psychological flexibility, self-efficacy, and rewired habits. Sessions allow introspection on smoking's role in life, often yielding lasting perspective shifts. NPR quotes Johnson: psilocybin occasions 'a shift in perspective and new sense of agency.'
Brain imaging from the trial (pending analysis) may reveal neuroplasticity enhancements, explaining transdiagnostic benefits for addictions, depression, and PTSD. Experts like Megan Piper (UW-Madison) hail it as an 'exciting prospect' for novel mechanisms amid stagnant quit rates.
Read the full JAMA studySafety and Tolerability in a Controlled Setting
No serious adverse events were linked to psilocybin; common effects like transient anxiety or nausea resolved quickly under supervision. The protocol mirrors FDA-approved psychedelic trials, emphasizing preparation, supportive environment ('set and setting'), and integration therapy. Limitations include non-blinding (expectancy bias) and a motivated, educated sample (89% White, high prior psychedelic use), but biochemical verification bolsters credibility.
Psilocybin's Schedule I status limits access, but breakthrough therapy designations for depression signal FDA openness; larger trials are underway.
Comparing to Gold Standards: Varenicline and Beyond
- Nicotine patch: ~10-20% six-month abstinence alone; 22.8% with CBT in trials.
- Varenicline: 25-33%, superior to patch but with nausea side effects.
- Psilocybin + CBT: 40.5% prolonged, potentially scalable if approved.
Psilocybin's single-dose model contrasts intensive regimens, promising cost savings long-term.
Broader Implications for Addiction Treatment
This trial advances psychedelics' role in addiction, following MDMA for PTSD (FDA breakthrough). US universities like NYU Langone (ongoing psilocybin RCT NCT05452772) and UCSF are expanding research. If replicated, psilocybin could save thousands of lives, reducing $300B annual smoking costs. Policy shifts, like Oregon's psilocybin services, pave therapeutic paths.
NPR coverage of the studyFuture Outlook: Larger Trials and University Innovations
Johnson's NIH-funded placebo-controlled trial will address blinding. Johns Hopkins' center trains researchers, fostering careers in psychedelic psychiatry. For aspiring academics, opportunities abound in higher ed research jobs and university jobs at pioneering institutions.
Stakeholders—from CDC to insurers—eye integration, but scalability hinges on FDA approval and therapist training. This study exemplifies US universities' role in transformative health research.
Careers in Psychedelic and Addiction Research
Johns Hopkins exemplifies growth in psychedelic science, with roles for psychiatrists, neuroscientists, and therapists. Explore higher ed career advice, faculty positions, and rate my professor for insights. Check higher-ed-jobs for openings driving breakthroughs like this.
